Futures
Access hundreds of perpetual contracts
TradFi
Gold
One platform for global traditional assets
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Introduction to Futures Trading
Learn the basics of futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to practice risk-free trading
Launch
CandyDrop
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
Pre-IPOs
Unlock full access to global stock IPOs
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
Promotions
AI
Gate AI
Your all-in-one conversational AI partner
Gate AI Bot
Use Gate AI directly in your social App
GateClaw
Gate Blue Lobster, ready to go
Gate for AI Agent
AI infrastructure, Gate MCP, Skills, and CLI
Gate Skills Hub
10K+ Skills
From office tasks to trading, the all-in-one skill hub makes AI even more useful.
GateRouter
Smartly choose from 30+ AI models, with 0% extra fees
Caught wind that Lauren Sabella stepped down from MannKind last year after wrapping up her operations role. She'd been brought in as EVP of Operations back in January 2025, then called it quits come July. Pretty standard executive shuffle in biotech tbh.
MNKD's been kind of flat lately though - down like 1.82% YTD when I checked. Market cap sitting around $1.79B, which honestly doesn't tell you much without comparing to peers. Trading volume's decent enough at 2.7M shares average.
The Lauren Sabella transition didn't seem to shake things up much from what I saw. These C-suite moves happen all the time in pharma. More curious about what their actual pipeline looks like and whether they're still focused on that endocrine business or pivoting. That's what'll actually move the needle for MNKD holders imo.